

4240-134

**SECTION I**  
**AMENDMENTS TO THE CLAIMS**

**RECEIVED  
CENTRAL FAX CENTER**

**APR 11 2008**

Please amend claims 9, 10 and 16 as set forth below.

**Complete Listing of the Claims**

Upon entry of the present amendment, the claims will stand as follows. The following listing of the claims will replace all prior versions and listings of the claims in the present application:

1. (Original) A surface expression vector comprising any one or two or more of pgsB, pgsC and pgsA genes encoding poly-gamma-glutamic acid synthase complex and a gene encoding a spike antigen protein or a nucleocapsid antigen protein of SARS coronavirus.
2. (Original) The surface expression vector according to claim 1, wherein the spike antigen protein is SARS SA, SARS SB, SARS SC, SARS SD or SARS SBC.
3. (Withdrawn) The surface expression vector according to claim 1, wherein the nucleocapsid antigen protein is SARS NA, SARS NB or SARS N.
4. (Original) The surface expression vector according to claim 2, wherein the vector is pHCE2LB:pgsA-SARS SA, pHCE2LB:pgsA-SARS SC or pHCE2LB:pgsA-SARS SBC.
5. (Withdrawn) The surface expression vector according to claim 3, wherein the vector is pHCE2LB:pgsA-SARS NB or pHCE2LB:pgsA-SARS N.
6. (Previously presented) A microorganism transformed by the expression vector of claim 1.
7. (Original) The microorganism according to claim 6, wherein the microorganism is selected from the group consisting of *E. coli*, *Salmonella typhi*, *Salmonella typhimurium*, *Vibrio cholerae*, *Mycobacterium bovis*, *Shigella*, *Bacillus*, lactic acid bacterium, *Staphylococcus*, *Listeria monocytogenes*, and *Streptococcus*.
8. (Original) A method for producing a spike antigen protein or a nucleocapsid antigen protein of SARS coronavirus comprising culturing the microorganism of claim 6.

4240-134

9. (Currently amended) A vaccine for prevention of SARS virus comprising the spike antigen protein or the nucleocapsid antigen protein ~~or the~~ produced by the method of claim 8, as an effective ingredient.

10. (Currently amended) The vaccine according to claim 9, wherein the antigen protein is an expressed form on the surface of the microorganism, a crudely extracted form or a purified form.

11. (Previously presented) The vaccine according to claim 9, wherein the vaccine is adapted to be taken by oral administration or in food.

12. (Previously presented) The vaccine according to claim 9, wherein the vaccine is adapted for subcutaneous or intra-peritoneal injection.

13. (Previously presented) The vaccine according to claim 9, wherein the vaccine is adapted for intranasal administration.

14. (Original) The method according to claim 8, wherein the microorganism is lactic acid bacterium.

15. (Previously presented) A lactic acid bacterium, which is produced by the method of claim 14, having the spike antigen protein or the nucleocapsid antigen protein of SARS coronavirus expressed on its surface.

16. (Currently amended) A vaccine for prevention of SARS comprising the lactic acid bacterium of claim 15, an antigen protein extracted from said lactic acid bacterium, or an antigen protein purified from said lactic acid bacterium as an effective ingredient.

17. (Previously presented) The vaccine according to claim 16, wherein the vaccine is adapted to be taken by oral administration or in food.

18. (Previously presented) The vaccine according to claim 16, wherein the vaccine is adapted for subcutaneous or intra-peritoneal injection.

19. (Previously presented) The vaccine according to claim 16, wherein the vaccine is adapted for intranasal administration.